Persaud Navindra, Chin Jessica, Walker Mark
Department of Family and Community Medicine, St. Michael's Hospital, Toronto ON; Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto ON; Department of Family and Community Medicine, University of Toronto, Toronto ON.
Keenan Research Centre of the Li Ka Shing Knowledge Institute, St Michael's Hospital, Toronto ON.
J Obstet Gynaecol Can. 2014 Apr;36(4):343-348. doi: 10.1016/S1701-2163(15)30611-3.
Doxylamine-pyridoxine is the first-line agent for the treatment of nausea and vomiting of pregnancy (NVP) according to Canadian guidelines, and this combination is commonly prescribed to pregnant women. There is limited evidence that doxylamine-pyridoxine is more effective than pyridoxine alone. There is stronger support for the safety of pyridoxine monotherapy than for the combination of doxylamine-pyridoxine during pregnancy, and some conflicting evidence links doxylamine-pyridoxine use to pyloric stenosis and childhood malignancies. The role of doxylamine-pyridoxine as the first-line pharmacological treatment for NVP in Canada should be reconsidered.
根据加拿大指南，多西拉敏-吡哆醇是治疗妊娠恶心和呕吐（NVP）的一线药物，这种复方制剂常用于孕妇。仅有有限的证据表明多西拉敏-吡哆醇比单独使用吡哆醇更有效。与孕期使用多西拉敏-吡哆醇复方制剂相比，有更强的证据支持吡哆醇单一疗法的安全性，并且一些相互矛盾的证据将多西拉敏-吡哆醇的使用与幽门狭窄和儿童恶性肿瘤联系起来。在加拿大，多西拉敏-吡哆醇作为NVP一线药物治疗的作用应重新考虑。
